Method of improving hematological parameters and brain dysfunction with ganoderma tsugae extract

Abstract

The invention relates to a method of improving hematological parameters and brain dysfunction by administrating an extract of Ganoderma tsugae . Particularly, the invention relates to a method of using an aqueous or ethanol extract to improve hematological parameters and brain dysfunction.

What is claimed is: 
     
         1 . A method for improving at least one hematological parameter or a brain dysfunction, comprising administering an effective amount of an ethanol or aqueous extract of  G. tsugae  obtained under high temperature to a subject. 
     
     
         2 . The method of  claim 1 , wherein the  G. tsugae  is  G. tsugae  RSH 1109. 
     
     
         3 . The method of  claim 1 , wherein the aqueous extract of  G. tsugae  is obtained by boiling a solution comprising  G. tsugae  and water in a ratio of 1:10 to 30 for 6 to 15 hours. 
     
     
         4 . The method of  claim 3 , wherein the heating time is 8 to 10 hours. 
     
     
         5 . The method of  claim 1 , wherein the aqueous  G. tsugae  aqueous extract comprises at least 2.5% (w/w) water-soluble polysaccharide. 
     
     
         6 . The method of  claim 5 , wherein the aqueous  G. tsugae  extract further comprises at least 1.0% (w/w) triterpene and at least 2.0×10 7  U/100 g of superoxide dismutase (SOD). 
     
     
         7 . The method of  claim 1 , wherein the aqueous  G. tsugae  extract comprises about 3.93% (w/w) water-soluble polysaccharide, about 1.96% (w/w) triterpene and about 4.31×10 7  U/100 g of SOD. 
     
     
         8 . The method of  claim 1 , wherein the ethanol extract of  G. tsugae  is obtained by heating a solution with  G. tsugae  and ethanol in a ratio of 1:10 to 30 at 70° C. to 85° C. for 80 to 120 hours 
     
     
         9 . The method of  claim 8 , wherein the heating time is about 100 hours. 
     
     
         10 . The method of  claim 8 , wherein the extract is obtained using 95% ethanol. 
     
     
         11 . The method of  claim 1 , wherein the ethanol  G. tsugae  extract comprises at least 0.1% (w/w) water-soluble polysaccharide. 
     
     
         12 . The method of  claim 11 , wherein the ethanol  G. tsugae  extract further comprises at least 10% (w/w) triterpene and 0.5×10 8  U/100 g of SOD. 
     
     
         13 . The method of  claim 1 , wherein the ethanol  G. tsugae  extract comprises about 0.22% (w/w) water-soluble polysaccharide. 
     
     
         14 . The method of  claim 13 , wherein the ethanol  G. tsugae  extract further comprises about 21.7% (w/w) triterpene and about 1.32×10 8  U/100 g of SOD. 
     
     
         15 . The method of  claim 1 , wherein the hematological parameter is distribution of RBC volume, viscosity of whole blood, RBC aggregation index, erythrocyte electrophoresis index, erythrocyte rigidity index, internal viscosity of erythrocyte or oxygen transport efficiency. 
     
     
         16 . A method for improving a brain dysfunction, comprising administering an effective amount of an ethanol or aqueous extract of  G. tsugae  obtained under high temperature to a subject. 
     
     
         17 . The method of  claim 1 , wherein the brain dysfunction is a cognitive disorder. 
     
     
         18 . The method of  claim 1 , wherein the brain dysfunction is memory impairment. 
     
     
         19 . The method of  claim 1 , wherein the brain dysfunction is age-associated memory impairment, mild cognitive impairment, delirium, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, mental retardation, cerebrovascular disease, affective disorders, psychotic disorders, Asperger's disorder, autism, neurotic disorders, attention deficit disorders, oppositional defiant disorder, conduct disorder, subdural hematoma, normal-pressure hydrocephalus, brain tumor, head trauma, or brain trauma. 
     
     
         20 . The method of  claim 1 , wherein the brain dysfunction is depression or anxiety, psychosis, Down's syndrome, stroke, traumatic brain injury, Huntington's disease AIDS associated dementia, schizophrenia, or attention deficit disorder.